加雷沙星（BMS 284756）对108株阴道加德纳菌临床分离株的体外活性
In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis.
作者信息
Goldstein Ellie J C, Citron Diane M, Merriam C Vreni, Warren Yumi A, Tyrrell Kerin L, Fernandez Helen T
机构信息
R. M. Alden Research Laboratory, Santa Monica-University of California Los Angeles Medical Center, 90404, USA.
出版信息
Antimicrob Agents Chemother. 2002 Dec;46(12):3995-6. doi: 10.1128/AAC.46.12.3995-3996.2002.
Abstract
Garenoxacin (BMS 284756) was active against 105 of 108 (97%) recent clinical Gardnerella vaginalis isolates at < or =2 micro g/ml by using the reference agar dilution method for anaerobes. Twenty-eight percent of isolates (31 of 108) were resistant to metronidazole, and 44% were resistant to doxycycline. All were susceptible to clindamycin and ampicillin-sulbactam.
摘要
采用厌氧菌参考琼脂稀释法，加替沙星（BMS 284756）对108株阴道加德纳菌临床分离株中的105株（97%）在浓度≤2μg/ml时具有活性。28%的分离株（108株中的31株）对甲硝唑耐药，44%对多西环素耐药。所有菌株对克林霉素和氨苄西林-舒巴坦敏感。
相似文献
1
In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis.加雷沙星（BMS 284756）对108株阴道加德纳菌临床分离株的体外活性
Antimicrob Agents Chemother. 2002 Dec;46(12):3995-6. doi: 10.1128/AAC.46.12.3995-3996.2002.
2
Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.加雷沙星（BMS-284756）及其他药物对厌氧临床分离株的活性。
Antimicrob Agents Chemother. 2003 Mar;47(3):910-6. doi: 10.1128/AAC.47.3.910-916.2003.
3
[In vitro activity of 5 new quinolones against Gardnerella vaginalis].
Pathol Biol (Paris). 1989 May;37(5):394-6.
4
In vitro activities of garenoxacin (BMS-284756) against 170 clinical isolates of nine Pasteurella species.加替沙星（BMS-284756）对9种巴斯德菌属170株临床分离株的体外活性
Antimicrob Agents Chemother. 2002 Sep;46(9):3068-70. doi: 10.1128/AAC.46.9.3068-3070.2002.
5
In vitro activity of seventeen antimicrobial agents against Gardnerella vaginalis.17种抗菌剂对阴道加德纳菌的体外活性
Eur J Clin Microbiol. 1982 Oct;1(5):298-300. doi: 10.1007/BF02019975.
6
In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.加替沙星（BMS - 284756）及其他抗菌药物对人型支原体和脲原体的体外敏感性及杀菌活性
Antimicrob Agents Chemother. 2003 Jan;47(1):161-5. doi: 10.1128/AAC.47.1.161-165.2003.
7
Antimicrobial susceptibilities of Gardnerella vaginalis.阴道加德纳菌的抗菌药敏性
Antimicrob Agents Chemother. 1993 Dec;37(12):2733-5. doi: 10.1128/AAC.37.12.2733.
8
Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.加雷沙星（BMS-284756）对环丙沙星敏感或耐药金黄色葡萄球菌的突变预防浓度。
Antimicrob Agents Chemother. 2003 Mar;47(3):1023-7. doi: 10.1128/AAC.47.3.1023-1027.2003.
9
Antibiotic resistance of Gardnerella vaginalis in recurrent bacterial vaginosis.复发性细菌性阴道病中阴道加德纳菌的抗生素耐药性
Indian J Med Microbiol. 2008 Apr-Jun;26(2):155-7. doi: 10.4103/0255-0857.40531.
10
Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).新型去氟喹诺酮类药物加替沙星（BMS 284756）对8331株社区获得性呼吸道感染分离菌株的比较活性：哨兵抗菌监测计划（1999 - 2001年）的北美结果
Diagn Microbiol Infect Dis. 2003 Apr;45(4):273-8. doi: 10.1016/s0732-8893(03)00002-6.
引用本文的文献
1
Gardnerella vaginalis population dynamics in bacterial vaginosis.细菌性阴道病中阴道加德纳菌的种群动态
Eur J Clin Microbiol Infect Dis. 2017 Jul;36(7):1269-1278. doi: 10.1007/s10096-017-2933-8. Epub 2017 Feb 14.
2
Advances in the Prevention of Infection-Related Preterm Birth.预防感染相关早产的进展
Front Immunol. 2015 Nov 16;6:566. doi: 10.3389/fimmu.2015.00566. eCollection 2015.
3
Draft Genome Sequence of a Metronidazole-Resistant Derivative of Gardnerella vaginalis Strain ATCC 14019.阴道加德纳菌ATCC 14019甲硝唑耐药衍生物的基因组序列草图
Genome Announc. 2015 Nov 12;3(6):e01345-15. doi: 10.1128/genomeA.01345-15.
4
Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review.局部应用氯化喹吖啶治疗阴道感染的研究综述
Arch Gynecol Obstet. 2016 Mar;293(3):469-84. doi: 10.1007/s00404-015-3914-8. Epub 2015 Oct 27.
5
Draft Genome Sequence of a Metronidazole-Resistant Gardnerella vaginalis Isolate.一株耐甲硝唑阴道加德纳菌分离株的基因组序列草图
Genome Announc. 2015 Sep 3;3(5):e00992-15. doi: 10.1128/genomeA.00992-15.
6
Bacterial vaginosis, Atopobium vaginae and nifuratel.细菌性阴道病、阴道阿托波菌与硝呋太尔。
Curr Clin Pharmacol. 2012 Feb 1;7(1):36-40. doi: 10.2174/157488412799218824.
7
Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis.早孕期应用克林霉素治疗异常阴道菌群预防自发性早产的系统评价和荟萃分析。
Am J Obstet Gynecol. 2011 Sep;205(3):177-90. doi: 10.1016/j.ajog.2011.03.047. Epub 2011 Apr 2.
8
In vitro activity of nifuratel on vaginal bacteria: could it be a good candidate for the treatment of bacterial vaginosis?硝呋太尔对阴道细菌的体外活性：它是否可能成为治疗细菌性阴道病的良好候选药物？
Antimicrob Agents Chemother. 2011 May;55(5):2490-2. doi: 10.1128/AAC.01623-10. Epub 2011 Feb 14.
9
Antibiotic susceptibility of Atopobium vaginae.阴道阿托波菌的抗生素敏感性
BMC Infect Dis. 2006 Mar 16;6:51. doi: 10.1186/1471-2334-6-51.
本文引用的文献
1
Gardnerella vaginalis isolated from patients with bacterial vaginosis and from patients with healthy vaginal ecosystems.从细菌性阴道病患者和阴道生态系统健康的患者中分离出阴道加德纳菌。
Clin Infect Dis. 2001 Oct 1;33(7):1022-7. doi: 10.1086/323030. Epub 2001 Sep 5.
2
Understanding the bacterial flora of the female genital tract.了解女性生殖道的细菌菌群。
Clin Infect Dis. 2001 Feb 15;32(4):e69-77. doi: 10.1086/318710. Epub 2001 Feb 9.
3
Comparative antianaerobic activity of BMS 284756.BMS 284756的抗厌氧活性比较
Antimicrob Agents Chemother. 2001 Feb;45(2):589-92. doi: 10.1128/AAC.45.2.589-592.2001.
4
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.新型去氟（6）喹诺酮BMS-284756的抗菌谱
Antimicrob Agents Chemother. 2000 Dec;44(12):3351-6. doi: 10.1128/AAC.44.12.3351-3356.2000.
5
In vitro activities of pazufloxacin, a novel injectable quinolone, against bacteria causing infections in obstetric and gynecological patients.
Chemotherapy. 1999 May-Jun;45(3):154-7. doi: 10.1159/000007177.
6
Recurrent bacterial vaginosis and metronidazole resistance in Gardnerella vaginalis.
Sex Transm Infect. 1998 Dec;74(6):455-6.
7
Therapy of bacterial vaginosis.
J Antimicrob Chemother. 1998 Jan;41(1):6-9. doi: 10.1093/jac/41.1.6.
8
Comparison of in vitro activities of DU-6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria.DU-6859a与其他氟喹诺酮类药物对日本厌氧菌分离株的体外活性比较。
Clin Infect Dis. 1996 Dec;23 Suppl 1:S31-5. doi: 10.1093/clinids/23.supplement_1.s31.
9
Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.脆弱拟杆菌群物种及其他厌氧菌对美罗培南、亚胺培南、哌拉西林、头孢西丁、氨苄西林/舒巴坦、克林霉素和甲硝唑的敏感性比较。
J Antimicrob Chemother. 1993 Mar;31(3):363-72. doi: 10.1093/jac/31.3.363.
10
Susceptibility of Gardnerella vaginalis to cephradine.阴道加德纳菌对头孢拉定的敏感性。
Antimicrob Agents Chemother. 1983 Sep;24(3):418-9. doi: 10.1128/AAC.24.3.418.
Zotero 插件